Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
0.815
+0.005 (0.58%)
Sep 18, 2024, 4:00 PM EDT - Market closed
Xilio Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Selling, General & Admin | 24.66 | 27 | 29.95 | 23.86 | 10.65 | 4.77 |
| Research & Development | 44.4 | 52.14 | 59.2 | 51.19 | 43.91 | 14.26 |
| Operating Expenses | 69.06 | 79.13 | 89.15 | 75.04 | 54.56 | 19.03 |
| Operating Income | -66.7 | -79.13 | -89.15 | -75.04 | -54.56 | -19.03 |
| Interest Expense | -0.4 | -0.7 | -0.8 | -0.6 | -0.6 | - |
| Other Non Operating Income (Expenses) | 2.55 | 3.43 | 1.73 | -0.16 | -0.06 | 1.72 |
| Pretax Income | -65.53 | -76.4 | -88.22 | -75.8 | -55.22 | -17.31 |
| Net Income | -65.53 | -76.4 | -88.22 | -75.8 | -55.22 | -17.31 |
| Net Income to Common | -65.53 | -76.4 | -88.22 | -75.8 | -55.22 | -17.31 |
| Shares Outstanding (Basic) | 44 | 27 | 27 | 6 | 1 | 0 |
| Shares Outstanding (Diluted) | 44 | 27 | 27 | 6 | 1 | 0 |
| Shares Change (YoY) | 60.24% | 0.38% | 388.59% | 970.34% | 27.97% | - |
| EPS (Basic) | -1.49 | -2.78 | -3.22 | -13.52 | -105.42 | -42.29 |
| EPS (Diluted) | -1.49 | -2.78 | -3.22 | -13.52 | -105.42 | -42.29 |
| Free Cash Flow | -17.37 | -69.11 | -77.59 | -81.85 | -38.28 | -18.56 |
| Free Cash Flow Per Share | -0.40 | -2.51 | -2.83 | -14.60 | -73.08 | -45.34 |
| EBITDA | -64.91 | -77.23 | -87.3 | -73.55 | -53.5 | -18.79 |
| D&A For EBITDA | 1.8 | 1.9 | 1.85 | 1.5 | 1.07 | 0.24 |
| EBIT | -66.7 | -79.13 | -89.15 | -75.04 | -54.56 | -19.03 |
Source: S&P Capital IQ. Standard template.
Financial Sources.